Every Form 4 that BIOADAPTIVES INC (BDPT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BDPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDPT filings page.
BIOADAPTIVES, INC. (symbol: BDPT) is the issuer of record for a Form 4 filing submitted to the SEC.
BIOADAPTIVES, INC. (symbol: BDPT) is the issuer of record for a Form 4 filing submitted to the SEC.
BioAdaptives, Inc. director Mark P. Frissora acquired 15,152 shares of Series D Convertible Preferred Stock as compensation for board services under a February 3, 2025 agreement. Each preferred share is convertible into 100 common shares, for 1,515,152 underlying shares, subject to a 4.9% beneficial ownership limit. The award increases his holdings to 103,923 preferred shares, which carry 100 votes per share and cannot be converted for six months after issuance except upon liquidation.
BioAdaptives, Inc. reported that director Mark P. Frissora received 12,500 shares of Series D Convertible Preferred Stock as compensation for board services. Each preferred share is convertible into 100 common shares, for 1,250,000 underlying common shares, subject to a 4.9% beneficial ownership cap. Following this grant, he holds 88,771 Series D preferred shares. The preferred shares carry 100 votes each and generally cannot be converted for six months, except upon liquidation.
BIOADAPTIVES, INC. director Mark P. Frissora reported an issuance of 4,717 shares of Series D Convertible Preferred Stock as compensation for board services under a Board of Directors Agreement. These preferred shares are convertible into 471,700 shares of common stock at a 100-for-1 ratio, subject to a 4.9% beneficial ownership limitation.
After this transaction, he holds 76,271 shares of Series D Convertible Preferred Stock directly. Each preferred share carries 100 votes on stockholder matters and cannot be converted until six months after issuance, except that conversion occurs immediately in a liquidation, with the conversion right not expiring.
BioAdaptives, Inc. director Mark P. Frissora reported an award of Series D Convertible Preferred Stock as board compensation. He received 4,808 shares of Series D Convertible Preferred Stock as compensation for board services under a Board of Directors Agreement dated February 3, 2025.
Each Series D share is convertible into 100 shares of common stock, so this grant is currently linked to 480,800 common shares, subject to a 4.9% beneficial ownership limitation. The preferred shares generally cannot be converted for six months after issuance, except that conversion occurs immediately in a liquidation. Each preferred share carries 100 votes on stockholder matters, and the right to convert does not expire. Following this grant, Frissora directly holds 71,554 shares of Series D Convertible Preferred Stock.
BIOADAPTIVES, INC. director Mark P. Frissora reported an other-type derivative transaction involving Series D Convertible Preferred Stock. He received 4,386 shares of Series D Convertible Preferred Stock as compensation for board services under a Board of Directors Agreement dated February 3, 2025, at a stated price of $0.0000 per share.
Each preferred share is convertible into 100 shares of common stock, for 438,600 underlying common shares, subject to a 4.9% beneficial ownership limitation. The preferred shares generally cannot be converted until six months after issuance, except upon liquidation, and each preferred share carries 100 votes on matters submitted to stockholders. Following this grant, Frissora directly holds 66,746 shares of Series D Convertible Preferred Stock.
BIOADAPTIVES, INC. director Mark P. Frissora reported an "other" transaction involving Series D Convertible Preferred Stock. He received 2,578 shares of this preferred stock as compensation for board services under a Board of Directors Agreement dated February 3, 2025, at a stated price of $0.00 per share, bringing his direct holdings to 62,360 shares.
Each share of Series D Convertible Preferred Stock is convertible into 100 shares of common stock, subject to a 4.9% beneficial ownership limitation, and generally cannot be converted for six months after issuance except upon liquidation. Each preferred share carries 100 votes on company matters, and the conversion right does not expire.
Bioadaptives, Inc. reported that director Mark P. Frissora received 2,565 shares of its Series D Convertible Preferred Stock on February 1, 2026, coded as a transaction "J" and issued at $0.00 per share as compensation for board services.
Following this grant, Frissora beneficially owns 59,779 Series D preferred shares. Each Series D share is convertible into 100 common shares, subject to a 4.9% beneficial ownership limitation, cannot be converted until six months after issuance (except on liquidation), carries 100 votes per share, and has a conversion right that does not expire.
BioAdaptives, Inc. director reports stock-based board compensation. A company director received 2,286 shares of BioAdaptives Series D Convertible Preferred Stock on 01/01/2026 as compensation for board services under a Board of Directors Agreement dated February 3, 2025. Each preferred share has a stated par value of $0.0001 and is convertible into 100 shares of common stock, for an underlying 228,600 common shares, subject to a 4.9% beneficial ownership limitation.
No Series D shares may be converted until six months after issuance, except that conversion occurs immediately upon liquidation. Each preferred share carries 100 votes in stockholder matters, and the conversion right does not expire. Following this transaction, the reporting person held 57,217 derivative securities in the form of Series D Convertible Preferred Stock, owned directly.
Bioadaptives, Inc. disclosed that a director filed a Form 4 reporting equity compensation in the form of preferred stock. On 12/01/2025, the director received 2,025 shares of Series D Convertible Preferred Stock as compensation for board services under a Board of Directors Agreement dated February 3, 2025. Each preferred share is convertible into 100 shares of common stock, for a total of 202,500 underlying common shares, but conversions are subject to a 4.9% beneficial ownership limitation.
The preferred shares generally cannot be converted until six months after issuance, except that conversion occurs immediately in a liquidation. Each preferred share carries 100 votes on stockholder matters and the conversion right does not expire. After this transaction, the reporting person beneficially owned 54,931 derivative securities, held directly.
BioAdaptives (BDPT) director filed a Form 4 reporting the acquisition of 1,382 shares of Series D Convertible Preferred Stock on 11/01/2025, issued as compensation for board services. The filing lists a $0 price for the derivative award.
Each Series D share is convertible into common stock at a 100:1 ratio, corresponding to 138,200 underlying common shares, subject to a 4.9% beneficial ownership limitation. The Series D shares become convertible six months after issuance (stated as 05/01/2026), with conversion occurring immediately in a liquidation scenario. Each Series D share carries 100 votes on matters of the issuer, and the right to convert does not expire.